Imuran (Azathioprine)

Azathioprine is converted inside cells to 6‑mercaptopurine, which blocks purine synthesis. This limits DNA production in rapidly dividing lymphocytes, reducing T‑ and B‑cell proliferation and thereby suppressing the immune response.

The dosage of Imuran is individualized. A qualified prescriber determines the appropriate amount based on the specific condition, patient weight, renal and hepatic function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for azathioprine in pregnancy and lactation are limited. It may be used only when the potential benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To request Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both azathioprine (Imuran) and mycophenolate mofetil are immunosuppressants used after transplantation and for autoimmune diseases. Azathioprine is a purine analogue that requires metabolic activation, while mycophenolate directly inhibits inosine monophosphate dehydrogenase. Their side‑effect profiles differ; azathioprine is more associated with bone‑marrow suppression, whereas mycophenolate often causes gastrointestinal upset.

Imuran tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and light, and keep out of reach of children. Do not store in bathrooms or near heat sources.

Imuran is taken orally as a tablet. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include severe bone‑marrow suppression leading to anemia, infections or bleeding; hepatotoxicity with elevated liver enzymes; and pancreatitis. Patients should promptly report unexplained fever, persistent fatigue, jaundice, abdominal pain, or unusual bruising to their physician.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with severe bone‑marrow suppression, active infections, or uncontrolled liver disease. Caution is also advised for individuals with thiopurine methyltransferase (TPMT) deficiency, as they are at higher risk for toxicity.